CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies

LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael H. Tardugno, the company’s chairman, president and chief executive officer, issued the following letter to stockholders providing an update on the ongoing data analysis from its Phase III OPTIMA Study with ThermoDox® plus radiofrequency ablation (RFA) in patients newly diagnosed with primary liver cancer, or hepatocellular carcinoma (HCC), as well as growing interest among clinical investigators in conducting studies with ThermoDox® as a monotherapy or in combination with other therapies.

To My Fellow Stockholders:

In response to the recent inquiries that we are receiving, I’d like to provide you with the following update regarding the OPTIMA Study’s ongoing analysis of probable futility findings, and ThermoDox®, generally.

As I have indicated in earlier press announcements and

Read More